U
LGND icon

UBS’s Ligand Pharmaceuticals LGND Stock Holding History

UBS’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$28K Sell
962
-641
-40% -$21.3K ﹤0.01% 7553
2014
Q2 		$62K Sell
1,603
-4,809
-75% -$195K ﹤0.01% 6579
2014
Q1 		$269K Sell
6,412
-1,763
-22% -$73.5K ﹤0.01% 4864
2013
Q4 		$268K Buy
8,175
+3,366
+70% +$110K ﹤0.01% 4977
2013
Q3 		$130K Sell
4,809
-802
-14% -$22.6K ﹤0.01% 5717
2013
Q2 		$131K Buy
+5,611
New +$101K ﹤0.01% 5566

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's LGND Position: Q3 2014 in Review

UBS increased its Ligand Pharmaceuticals (LGND) stake by 4.3% in Q3 2014, buying an estimated $22.8K and bringing the position to 16,655 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #4301.

UBS first reported a position in LGND in Q2 2013 and has held it in 6 quarters since. The position peaked at $963K in Q1 2014. 174 funds tracked by Wall St. Rank hold LGND as of Q3 2014.

  • UBS held 16,655 shares of Ligand Pharmaceuticals worth $488K as of Q3 2014.
  • UBS bought 686 Ligand Pharmaceuticals shares in Q3 2014, an estimated $22.8K.
  • Ligand Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4301 holding.
  • UBS first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Ligand Pharmaceuticals position peaked at $963K in Q1 2014.
  • 174 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.